Ipsen: data presented at CIFP and SAG

(CercleFinance.com) - Ipsen announces the presentation of data at the American Association for the Study of Liver Diseases (AASLD) congress evaluating the efficacy and long-term safety profile of Bylvay in two open-label phase III extension studies.


The pharmaceutical company highlights an abstract with new data (n°5045) on PEDFIC 2 in progressive familial intrahepatic cholestasis (PFIC), and an oral presentation on ASSERT-EXT (n°50) in Alagille syndrome (AS).

Data showing sustained efficacy and improvement in height, weight and sleep measurements were observed in patients treated with Bylvay for at least 72 weeks in both rare cholestatic diseases, it says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.